Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy

被引：13
作者：
Banach, Monika [1 ,2 ]
Borowicz, Kinga K. [2 ]
Czuczwar, Stanislaw J. [1 ,3 ]
机构：
[1] Med Univ Lublin, Dept Pathophysiol, PL-20090 Lublin, Poland
[2] Med Univ Lublin, Dept Pathophysiol, Independent Unit Expt Neuropathophysiol, PL-20090 Lublin, Poland
[3] Inst Rural Hlth, Dept Physiopathol, PL-20092 Lublin, Poland
来源：
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2015年 / 11卷 / 04期
关键词：
epilepsy; eslicarbazepine; eslicarbazepine acetate; partial seizures; PARTIAL-ONSET SEIZURES; STEADY-STATE PHARMACOKINETICS; MAXIMAL ELECTROSHOCK TEST; GATED SODIUM-CHANNELS; OPEN-LABEL EXTENSION; ACETATE BIA 2-093; LONG-TERM SAFETY; ANTIEPILEPTIC DRUGS; ISOBOLOGRAPHIC ANALYSIS; HEALTHY-SUBJECTS;
D O I：
10.1517/17425255.2015.1021686
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Introduction: Eslicarbazepine acetate (ESL) is a novel antiepileptic drug registered as the adjunctive treatment of partial-onset seizures in adults. As a third-generation medication, ESL is believed to have favorable efficacy/safety profile and pharmacokinetic properties in comparison with related drugs (carbamazepine and oxcarbazepine). Areas covered: The aim of the paper was to evaluate pharmacodynamic and pharmacokinetic properties of ESL with aspect to epilepsy treatment. The review of the scientific literature was based on the PubMed database, Clinical Trials, FDA and European Medicines Agency websites to elicit current information on drug metabolism, mechanism of action and efficacy/safety profile. Expert opinion: Results of clinical trials indicate that ESL possessed a favorable profile of anticonvulsant efficacy and tolerability as an add-on therapy in adult patients at daily doses of 800 and 1200 mg. Pediatric trials are in progress and their results will allow to characterize a role of ESL in the treatment of epilepsy in children.
引用
收藏
页码：639 / 648
页数：10
相关论文
共 64 条
[21]   Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker [J].
Falcao, Amilcar ;
Maia, Joana ;
Almeida, Luis ;
Mazur, Dago ;
Gellert, Manfred ;
Soares-da-Silva, Patricio .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2007, 28 (05) :249-256
[22]   Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects [J].
Falcao, Amilcar ;
Pinto, Roberto ;
Nunes, Teresa ;
Soares-da-Silva, Patricio .
EPILEPSY RESEARCH, 2013, 106 (1-2) :244-249
[23]   Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women [J].
Falcao, Amilcar ;
Vaz-da-Silva, Manuel ;
Gama, Helena ;
Nunes, Teresa ;
Almeida, Luis ;
Soares-da-Silva, Patricio .
EPILEPSY RESEARCH, 2013, 105 (03) :368-376
[24]   Pharmacokinetics, Drug Interactions and Exposure-Response Relationship of Eslicarbazepine Acetate in Adult Patients with Partial-Onset Seizures Population Pharmacokinetic and PharmacokineticiPharmacodynamic Analyses [J].
Falcao, Amilcar ;
Fuseau, Eliane ;
Nunes, Teresa ;
Almeida, Luis ;
Soares-da-Silva, Patricio .
CNS DRUGS, 2012, 26 (01) :79-91
[25]   Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures [J].
Gil-Nagel, A. ;
Lopes-Lima, J. ;
Almeida, L. ;
Maia, J. ;
Soares-da-Silva, P. .
ACTA NEUROLOGICA SCANDINAVICA, 2009, 120 (05) :281-287
[26]   Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Integrated analysis of pooled data from double-blind phase III clinical studies [J].
Gil-Nagel, Antonio ;
Elger, Christian ;
Ben-Menachem, Elinor ;
Halasz, Peter ;
Lopes-Lima, Jose ;
Gabbai, Alberto A. ;
Nunes, Teresa ;
Falcao, Amilcar ;
Almeida, Luis ;
Soares-da-Silva, Patricio .
EPILEPSIA, 2013, 54 (01) :98-107
[27]   Does Mechanism of Drug Action Matter to Inform Rational Polytherapy in Epilepsy? [J].
Giussani, Giorgia ;
Beghi, Ettore .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2013, 12 (03) :426-435
[28]   Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine [J].
Hainzl, D ;
Parada, A ;
Soares-da-Silva, P .
EPILEPSY RESEARCH, 2001, 44 (2-3) :197-206
[29]   Long-term efficacy and safety of eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy [J].
Halasz, Peter ;
Cramer, Joyce A. ;
Hodoba, Danilo ;
Czlonkowska, Anna ;
Guekht, Alla ;
Maia, Joana ;
Elger, Christian ;
Almeida, Luis ;
Soares-da-Silva, Patricio .
EPILEPSIA, 2010, 51 (10) :1963-1969
[30]   Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide [J].
Hebeisen, Simon ;
Pires, Nuno ;
Loureiro, Ana I. ;
Bonifacio, Maria Joao ;
Palma, Nuno ;
Whyment, Andrew ;
Spanswick, David ;
Soares-da-Silva, Patricio .
NEUROPHARMACOLOGY, 2015, 89 :122-135
1234567